Evaluation of Directly Acting Antivirals in Treatment of Egyptian Patients with Chronic Hepatitis C Genotype 4

Abstract

hronic hepatitis C is a major health problem globally. Because, chronic hepatitis C infection is a leading cause of liver cirrhosis or hepatocellular carcinoma and is the principal indication for liver transplantation. The selection of the most effective and safe drugs may be pivotal for the treatment of chronically HCV-infected patients to reduce HCV-related morbidity or mortality. Although blood screening and other preventive measures have reduced the incidence of HCV in some parts of the world, infection with this virus remains a significant worldwide health concern. The principal challenges to reducing this burden lie in the identification and delivery of care to the major infected populations, and the provision of more effective therapies for the eradication of HCV. This study was designed to assess the SVR 12 and SVR 24 in Egyptian patients with chronic hepatitis C with different regimens based on directly acting antivirals drugs (sofosbuvir, simeprevir, daclatasvir and ribavirin). This study was conducted on 100 patients with chronic HCV infection recruited from patients attending the outpatient clinic of Ain Shams University Hospitals. Those patients started treatment on January 2016 and followed during